Bayer

(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in moderate or severe exacerbations at 52 weeks. However, the AERIFY-2 study did not achieve the … Read the full press release →

(IN BRIEF) Sanofi and Sobi have renewed their partnership with the World Federation of Hemophilia (WFH) to support the WFH Humanitarian Aid Program for up to five years. The new agreement includes the donation of up to 100 million international … Read the full press release →

(IN BRIEF) Borealis and Hosokawa Alpine have successfully developed MDO films using BorShape™ polyethylene that are thinner than industry norms—just 15 microns compared to the standard 23—without compromising mechanical strength or process stability. Tested in early 2025, these films offer … Read the full press release →

(IN BRIEF) Bayer has opened a new maize seed facility in Kabwe, Zambia, with a 32-million-euro investment that triples its current production capacity. The facility, part of Bayer’s growth strategy in Africa, is expected to provide high-yielding maize seeds to … Read the full press release →

(IN BRIEF) A collaborative study led by Bayer and Hurdle, in partnership with top academic institutions including the University of Birmingham and the University of Edinburgh, has introduced and validated InflammAge—a novel, non-invasive saliva-based biomarker that quantifies systemic chronic inflammation, … Read the full press release →

(IN BRIEF) Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupixent would be the first targeted medicine for BP in the U.S., with the FDA’s decision expected … Read the full press release →

(IN BRIEF) Recent studies suggest that current cardiovascular risk assessment methods may be inadequate and call for a more personalized approach. Tools like carotid ultrasound offer promising solutions for more precise evaluations, enabling targeted interventions such as aspirin therapy, which … Read the full press release →

(IN BRIEF) SCHOTT Pharma’s AGM on February 4, 2025, revealed strong fiscal results for FY 2024, including exceeding revenue targets and a promotion to the MDAX. Shareholders approved all agenda items, including the appointment of Dr. Wolfram Carius to the … Read the full press release →